Connecticut is currently home to 1248 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
The Pivotal Study of RapidPulseTM Aspiration System
Recruiting
The goal of this clinical trials is to demonstrate the safety and effectiveness for the RapidPulseTM Aspiration System in patients experiencing acute ischemic stroke within 8 hours of symptom onset or last seen normal. Subjects will undergo mechanical thrombectomy (a procedure to remove a clot in the brain which is preventing blood flow), with the RapidPulseTM Aspiration System. Participation in the trial is for 90 days.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/11/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Acute Ischemic Stroke
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
Recruiting
This registry evaluates patient characteristics, real-world treatment patterns, and short- and long-term outcomes in a population of patients in the United States and Europe with symptomatic obstructive hypertrophic cardiomyopathy (HCM) who are receiving mavacamten, receiving other treatment for obstructive HCM, or not receiving treatment for obstructive HCM due to intolerance or failure of prior treatment. United States Sub-Study: The purpose of this study is to evaluate the safety of mavacamt... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Hartford HealthCare, Hartford, Connecticut
Conditions: Obstructive Hypertrophic Cardiomyopathy
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Recruiting
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is that ficlatuzumab combined with cetuximab is superior to cetuximab alone in terms of progression-free survival and/or overall survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Yale School of Medicine - Smilow Cancer Hospital, New Haven, Connecticut
Conditions: Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Type 1 Diabetes Extension Study
Recruiting
This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D). This observational study will: * follow participants to determine how long they continue to produce insulin, and * will also assess how changes in the immune system over time relate to the ability to produce insulin. This information could help design better therapies for... Read More
Gender:
ALL
Ages:
Between 8 years and 35 years
Trial Updated:
04/09/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Type 1 Diabetes Mellitus, T1DM, T1D
The Recovery in Stroke Using PAP Study
Recruiting
The proposed study is a randomized controlled trial among an anicipated 180 participants with acute ischemic stroke and mod/severe OSA diagnosed by ambulatory polysomnography (PSG) comparing PAP treatment with usual care concerning the primary outcome of functional recovery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Ischemic Stroke, Obstructive Sleep Apnea
Substance Misuse and Family Violence Treatment Fathers
Recruiting
This study involves a randomized controlled trial of Fathers for Change (F4C) compared to Individual Drug Counseling (IDC) with a sample of 280 fathers enrolled in substance use (SU) treatment within community or veterans (VA) healthcare settings to (a) demonstrate F4C efficacy compared to IDC in reducing SU and family violence (FV) at end of treatment, 3- and 6-month post-treatment follow-up, and (b) document improved emotion regulation as the mechanism within F4C that results in reduced SU and... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Yale University Child Study Center, New Haven, Connecticut
Conditions: Substance Misuse, Violence, Domestic, Child Abuse
OMAR Opioid Use Disorder
Recruiting
The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Connecticut Mental Health Center, Clinical Neuroscience Research Unit, New Haven, Connecticut
Conditions: Healthy Control, Opioid Use Disorder
Imaging SV2A in Mood Disorders
Recruiting
This study is designed to examine SV2A density in MDD and PTSD as a correlate of synaptic density, and to determine whether ketamine administration will reverse the synaptic loss in vivo in human subjects. To our knowledge, this is the first human study to examine SV2A in vivo in MDD and PTSD and to use the first known drug (ketamine) that rapidly reverses synaptic loss to determine whether ketamine administration could restore some of the structural changes associated with depression and PTSD.... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/08/2025
Locations: PET Center, New Haven, Connecticut
Conditions: Major Depressive Disorder, Post-Traumatic Stress Disorder
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
Recruiting
Fetal complete (i.e., third degree, 3°) atrioventricular block (AVB), identified in the 2nd trimester of pregnancy in an otherwise normally developing heart, is almost universally associated with maternal anti-Ro autoantibodies and results in death in a fifth of cases. To date treatment of 3° AVB has been ineffective in restoring normal rhythm (NR) which may be because current surveillance is limited to once- weekly fetal echocardiograms. It is hypothesized that there may be a vital transition p... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/08/2025
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: AVB - Atrioventricular Block, Fetal AVB
Regulating Blood Pressure During Recovery From Intracerebral Hemorrhage and Ischemic Stroke
Recruiting
The purpose of this research study is to determine whether blood pressure treatment regimens with spironolactone are better than blood pressure treatment regimens without spironolactone at lowering blood pressure in stroke survivors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/08/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Intracerebral Hemorrhage, Spironolactone, Ischemic Stroke
Alcohol-ROC-Training
Recruiting
The goal of the proposed study is to examine whether brief training in regulation of craving (ROC-T) affects alcohol drinking. The study will consist of a basic screening (phone and online), and in person visit to determine eligibility and conduct pre-intervention baseline assessments, 1-4 training (ROC-T) visits, a post-intervention assessment visit, and 1-2 phone/online follow up assessments.The two active conditions of ROC-T are based on cognitive-behavioral treatments (CBT) and mindfulness-b... Read More
Gender:
ALL
Ages:
Between 18 years and 26 years
Trial Updated:
04/08/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Binge Drinking, Heavy Drinking, Young Adult, Heavy Drinker
Addictive Threshold of Nicotine
Recruiting
To determine the nicotine threshold dose(s) for discrimination, subjective-rewarding effects, -and reinforcement in smokers with different levels of dependence.
Gender:
ALL
Ages:
Between 21 years and 59 years
Trial Updated:
04/08/2025
Locations: VA Healthcare System, West Haven, Connecticut
Conditions: Smoking Addiction